- United States
- /
- Chemicals
- /
- NYSE:CBT
Assessing Cabot (CBT) Valuation After Recent Pullback And Discounted P/E Multiple
Cabot’s recent share performance and business snapshot
Cabot (CBT) has seen mixed share performance recently, with a modest 1 day gain, a slight 7 day pullback, and a larger decline over the past month, alongside a positive return over the past 3 months.
The specialty chemicals group, headquartered in Boston, reports annual revenue of US$3,607.0 million and net income of US$306.0 million. Its operations span Reinforcement Materials, Performance Chemicals, and smaller unallocated activities.
See our latest analysis for Cabot.
At a share price of US$68.59, Cabot’s recent 1 day gain contrasts with a 30 day share price return of 8.33% decline and a 1 year total shareholder return of 14.85% loss. This suggests momentum has cooled after earlier strength over longer periods.
If you are weighing Cabot’s recent pullback against opportunities elsewhere in materials, this can be a good moment to see what is happening across 8 top copper producer stocks
With Cabot trading at US$68.59, reportedly at a 28% discount to one intrinsic value estimate and below an average analyst price target, investors may ask whether this represents a genuine value opportunity or whether the market is already pricing in future growth.
Preferred P/E of 11.7x: Is it justified?
Cabot is trading on a P/E of 11.7x, while the last close sits at $68.59 and its shares are flagged as trading below some valuation yardsticks, suggesting the earnings multiple is on the lower side compared with peers.
The P/E ratio compares the current share price with earnings per share and helps you see how much the market is paying for each dollar of Cabot’s earnings. For a specialty chemicals group with $3,607.0 million in revenue and $306.0 million in net income, this ratio gives a quick read on whether earnings are being priced richly or conservatively.
Cabot is described as good value on this measure both versus direct peers, where its 11.7x P/E sits under a peer average of 18.8x, and versus the broader US Chemicals industry, where the average P/E is 27.1x. That is a meaningful gap, which indicates the market is paying less for Cabot’s earnings than for many other chemicals names on the same metric.
See what the numbers say about this price — find out in our valuation breakdown.
Result: Price-to-earnings of 11.7x (UNDERVALUED)
However, the recent 1-year total shareholder return of a 14.85% loss and exposure to cyclical end markets could still weigh on how quickly any value case plays out.
Find out about the key risks to this Cabot narrative.
Another view on value: what the DCF model says
While Cabot’s 11.7x P/E suggests the shares are inexpensive versus peers, our DCF model tells a similar story from a different angle. With the stock at $68.59 and the model indicating a value of $95.13, Cabot screens as undervalued on projected cash flows too. The question is whether you trust today's earnings snapshot or a longer term cash flow picture more.
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Cabot for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 49 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
With mixed signals across valuation, returns and future cash flow assumptions, it makes sense to act promptly, review the full picture, and weigh the 2 key rewards and 1 important warning sign.
Looking for more investment ideas?
If Cabot is on your radar but you want a broader watchlist, use these filters now so you are not catching up with the market later.
- Target resilient companies first by checking out 72 resilient stocks with low risk scores that may help you keep volatility in check.
- Spot potential mispricings by scanning 49 high quality undervalued stocks that combine solid fundamentals with more attractive entry points.
- Position your portfolio for income by reviewing 13 dividend fortresses that aim to balance higher yields with stability.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
Druckenmiller says cheap money's days are numbered. Boring, self-funding companies could be the opportunity.

Leverage on its own is close to useless as a screen right now, because so much corporate debt was termed out at 2 to 3% and has not repriced. A business at three times leverage with nothing due until 2031 is in a completely different position from the same ratio rolling next year. Screen on weighted average maturity and the schedule behind it.
In my view, Insurance companies are best positioned for this.
Which payment stocks actually get paid?

About NYSE:CBT
Cabot
Operates as a specialty chemicals and performance materials company.
Excellent balance sheet established dividend payer.